Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease

Gustavo Basurto-Islas; Julie Blanchard; Yunn Chyn Tung; Jose R. Fernandez; Michael Voronkov; Maxwell Stock; Sherry Zhang; Jeffry B. Stock; Khalid Iqbal

doi:10.1016/j.neurobiolaging.2014.06.012

Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease

Gustavo Basurto-Islas, Julie Blanchard, Yunn Chyn Tung, Jose R. Fernandez, Michael Voronkov, Maxwell Stock, Sherry Zhang, Jeffry B. Stock, Khalid Iqbal

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2PP2A, or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.

Original language	English (US)
Pages (from-to)	2701-2712
Number of pages	12
Journal	Neurobiology of Aging
Volume	35
Issue number	12
DOIs	https://doi.org/10.1016/j.neurobiolaging.2014.06.012
State	Published - Dec 1 2014

All Science Journal Classification (ASJC) codes

Clinical Neurology
Geriatrics and Gerontology
Aging
General Neuroscience
Developmental Biology

Keywords

Adenoassociated virus vector serotype 1
Aβ
Coffee
Cognitive impairment
Eicosanoyl-5-hydroxytryptamide
Hyperphosphorylation of tau
Inhibitor-2 of protein phosphatase-2A
Methylation of protein phosphatase-2A
Protein phosphatase-2A
Rat model of sporadic Alzheimer's disease
SET
Tau

Access to Document

10.1016/j.neurobiolaging.2014.06.012

Cite this

@article{a87379d186fc414ea021d3a6afbb58d6,

title = "Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease",

abstract = "A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2PP2A, or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.",

keywords = "Adenoassociated virus vector serotype 1, Aβ, Coffee, Cognitive impairment, Eicosanoyl-5-hydroxytryptamide, Hyperphosphorylation of tau, Inhibitor-2 of protein phosphatase-2A, Methylation of protein phosphatase-2A, Protein phosphatase-2A, Rat model of sporadic Alzheimer's disease, SET, Tau",

author = "Gustavo Basurto-Islas and Julie Blanchard and Tung, {Yunn Chyn} and Fernandez, {Jose R.} and Michael Voronkov and Maxwell Stock and Sherry Zhang and Stock, {Jeffry B.} and Khalid Iqbal",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.neurobiolaging.2014.06.012",

language = "English (US)",

volume = "35",

pages = "2701--2712",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease

AU - Basurto-Islas, Gustavo

AU - Blanchard, Julie

AU - Tung, Yunn Chyn

AU - Fernandez, Jose R.

AU - Voronkov, Michael

AU - Stock, Maxwell

AU - Zhang, Sherry

AU - Stock, Jeffry B.

AU - Iqbal, Khalid

PY - 2014/12/1

Y1 - 2014/12/1

N2 - A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2PP2A, or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.

AB - A minor component of coffee unrelated to caffeine, eicosanoyl-5-hydroxytryptamide (EHT), provides protection in a rat model for Alzheimer's disease (AD). In this model, viral expression of the phosphoprotein phosphatase 2A (PP2A) endogenous inhibitor, the I2PP2A, or SET protein in the brains of rats leads to several characteristic features of AD including cognitive impairment, tau hyperphosphorylation, and elevated levels of cytoplasmic amyloid-β protein. Dietary supplementation with EHT for 6-12 months resulted in substantial amelioration of all these defects. The beneficial effects of EHT could be associated with its ability to increase PP2A activity by inhibiting the demethylation of its catalytic subunit PP2Ac. These findings raise the possibility that EHT may make a substantial contribution to the apparent neuroprotective benefits associated with coffee consumption as evidenced by numerous epidemiologic studies indicating that coffee drinkers have substantially lowered risk of developing AD.

KW - Adenoassociated virus vector serotype 1

KW - Aβ

KW - Coffee

KW - Cognitive impairment

KW - Eicosanoyl-5-hydroxytryptamide

KW - Hyperphosphorylation of tau

KW - Inhibitor-2 of protein phosphatase-2A

KW - Methylation of protein phosphatase-2A

KW - Protein phosphatase-2A

KW - Rat model of sporadic Alzheimer's disease

KW - SET

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84911446629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911446629&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2014.06.012

DO - 10.1016/j.neurobiolaging.2014.06.012

M3 - Article

C2 - 25034344

AN - SCOPUS:84911446629

SN - 0197-4580

VL - 35

SP - 2701

EP - 2712

JO - Neurobiology of Aging

JF - Neurobiology of Aging

IS - 12

ER -

Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this